Buscar en
Acta Otorrinolaringológica Española
Toda la web
Inicio Acta Otorrinolaringológica Española Trends in Recurrent Respiratory Papillomatosis Treatment
Journal Information
Vol. 72. Issue 2.
Pages 109-120 (March - April 2021)
Share
Share
Download PDF
More article options
Visits
16
Vol. 72. Issue 2.
Pages 109-120 (March - April 2021)
Review article
Trends in Recurrent Respiratory Papillomatosis Treatment
Tendencias en el tratamiento de la papilomatosis respiratoria recurrente
Visits
16
Samir A. Ballestas, Sandeep Shelly, Roberto M. Soriano, Adam Klein
Corresponding author
adam.klein@emory.edu

Corresponding author.
Departamento de Otorrinolaringología y Cirugía de Cabeza y Cuello, Emory University School of Medicine, Atlanta, United States
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Tables (2)
Table 1. Study Characteristics With Results.
Table 2. Previously Failed Adjuvant Treatments.
Show moreShow less
Abstract

Recurrent respiratory papillomatosis (RRP) consist of benign tumours along the airway caused by human papillomavirus infection. Papillomas may cause changes in phonation and obstruct the airway. The purpose of this study was to evaluate the different surgical and adjuvant therapies available for the treatment of this condition reported between 2014 and 2018. A PubMed search was performed for RRP treatment articles published between 2014 and 2018. Forty articles that encompassed 1425 patients with RRP met the criteria. Of these, 24 articles evaluate the use of adjuvant therapies such as bevacizumab, human papillomavirus vaccine and cidofovir. There has been an increase in adjuvant therapy options for RRP in the literature in recent years. An awareness of these options highlights gaps and opportunities in the care of these patients, opens the door to new protocols to control disease and increase intersurgical intervals, and guides us towards new management paradigms in the future.

Keywords:
Recurrent respiratory papillomatosis
Laryngeal papillomatosis
Human papilloma virus
Bevacizumab
Human papillomavirus vaccine
Resumen

La papilomatosis respiratoria recurrente (PRR) consiste en tumores benignos en las vías respiratorias causados por la infección del virus del papiloma humano. Las lesiones pueden provocar cambios en la fonación y obstruir las vías respiratorias. El objetivo de este estudio es evaluar las diferentes terapias quirúrgicas y adyuvantes disponibles para el tratamiento de esta afección que se han reportado en los años recientes. Se realizó una búsqueda en PubMed de artículos sobre el tratamiento de la PPR publicados entre 2014 y 2018. De los encontrados, 40 artículos con 1.425 pacientes con PRR cumplieron con los criterios. De estos, 24 artículos evaluaban el uso de terapias adyuvantes como el bevacizumab, el cidofovir y la vacuna contra el virus del papiloma humano. Ha habido un aumento en las opciones terapéuticas adyuvantes para la PRR en los últimos años. El conocimiento de estas opciones resalta las lagunas y oportunidades en la atención de estos pacientes, abre la puerta a nuevos protocolos para controlar la enfermedad, aumenta los intervalos quirúrgicos y nos guía hacia nuevos caminos en el futuro.

Palabras clave:
Papilomatosis respiratoria recurrente
Papilomatosis laríngea
Virus del papiloma humano
Bevacizumab
Vacuna contra el virus del papiloma humano

Article

These are the options to access the full texts of the publication Acta Otorrinolaringológica Española
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Acta Otorrinolaringológica Española

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos